Cyclo Selling And Marketing Expenses from 2010 to 2025

CYTH Stock  USD 0.70  0.08  9.94%   
Cyclo Therapeutics' Selling And Marketing Expenses is decreasing with slightly volatile movements from year to year. Selling And Marketing Expenses is estimated to finish at 6,704 this year. For the period between 2010 and 2025, Cyclo Therapeutics, Selling And Marketing Expenses quarterly trend regression had mean deviation of  2,971 and range of 14.8 K. View All Fundamentals
 
Selling And Marketing Expenses  
First Reported
2012-03-31
Previous Quarter
501
Current Value
441
Quarterly Volatility
2.2 K
 
Yuan Drop
 
Covid
Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 21.1 K, Interest Expense of 181.7 K or Total Revenue of 1 M, as well as many indicators such as Price To Sales Ratio of 22.79, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Latest Cyclo Therapeutics' Selling And Marketing Expenses Growth Pattern

Below is the plot of the Selling And Marketing Expenses of Cyclo Therapeutics over the last few years. It is Cyclo Therapeutics' Selling And Marketing Expenses historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Selling And Marketing Expenses10 Years Trend
Slightly volatile
   Selling And Marketing Expenses   
       Timeline  

Cyclo Selling And Marketing Expenses Regression Statistics

Arithmetic Mean8,555
Geometric Mean7,808
Coefficient Of Variation44.67
Mean Deviation2,971
Median7,847
Standard Deviation3,821
Sample Variance14.6M
Range14.8K
R-Value(0.30)
Mean Square Error14.3M
R-Squared0.09
Significance0.26
Slope(238.29)
Total Sum of Squares219M

Cyclo Selling And Marketing Expenses History

2025 6703.63
2024 3511.8
2023 3902.0
202213.1 K
202118.3 K
2020 5006.0
2019 5885.0

About Cyclo Therapeutics Financial Statements

Investors use fundamental indicators, such as Cyclo Therapeutics' Selling And Marketing Expenses, to determine how well the company is positioned to perform in the future. Although Cyclo Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Selling And Marketing Expenses3.5 K6.7 K

Currently Active Assets on Macroaxis

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:
Check out the analysis of Cyclo Therapeutics Correlation against competitors.
For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.90)
Revenue Per Share
0.046
Quarterly Revenue Growth
0.051
Return On Assets
(2.82)
Return On Equity
(226.64)
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.